Joaquin Mateo a, Karim Fizazi b, Silke Gillessen c, Axel Heidenreich d, Raquel Perez-Lopez a,
Wim J.G. Oyen e, Neal Shore f, Matthew Smith g, Christopher Sweeney h, Bertrand Tombal i,
Scott A. Tomlins j, Johann S. de Bono e,*
The publication titled “Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer” appeared in The New England Journal of Medicine online yesterday and will appear in the June 28 print edition. Click here to read
Two associated articles, an Editorial titled “Progress in Nonmetastatic Prostate Cancer” click here to read
and a Perspective titled “Metastasis-free Survival — A New End Point in Prostate Cancer Trials” also appeared in the same issue of The New England Journal of Medicine. Click here to read
Dr Neal Shore is joined by Dr Simon Chowdhury, Prof Matthew Smith and Prof Boris Hadaschik at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Dr Neal Shore speaks to Prof Karim Fizazi at ASCO 2018 about the changing landscape of treatments for prostate cancer, discussing immunotherapies, PARP inhibitors and PSMA testing as future targets and treatments.
Neal D. Shore, Lawrence I. Karsh, Eric T. Gross, Christopher M. Pieczonka, Philip J. Aliotta, Christopher J. Skomra, Lee E. Ponsky, Peter T. Nieh, Misop Han, Daniel A. Hamstra
• E. David Crawford, Paul F. Schellhammer, David G. McLeod, Judd W. Moul, Celestia S. Higano, Neal Shore, Louis Denis, Peter Iversen, Mario A. Eisenberger, Fernand Labrie
Dr. Shore, co -author
2017 was a pivotal year for the growth of value-based care. For many practices, this meant completing their first performance year as part of the Merit-Based Incentive Payment System (MIPS). A much smaller percentage of practices was able to participate in approved advanced Alternative Payment Models (APMs).
Dr. Shore, co -author
Prostate cancer is a significant burden and cause of mortality in Latin America. This article reviews the treatment options
for patients with metastatic castration-resistant prostate cancer (mCRPC) and provides consensus recommendations to
assist Latin American prostate cancer specialists with clinical decision making.
There has been a limited number of new therapeutics, particularly in the area of patients who would benefit from advanced systemic bladder cancer treatments. Dr. Neal Shore reviews some pioneering work from the past such as MVAC and gemcitabine platinum based combinations but he notes those treatments are where things were left for many many years. The development of immuno-oncology is revolutionizing how physicians should be thinking about bladder and renal cancer treatments.
